Regulatory-affairs lead must resolve whether to resubmit, meet, or pause

Situation

To resubmit, meet, or sits with regulatory-affairs lead because a literature paper the 505(b)(2) package leans on getting retracted hit a mid-size sponsor after a complete response letter. Evidence is advisory-committee question list that exposes a weak secondary endpoint; write the Pharma & Life Sciences FDA Response and Labeling option that extract can carry.

Decision

Regulatory-affairs lead in a mid-size sponsor after a complete response letter must choose To resubmit, meet, / Pause the program using advisory-committee question list that exposes a weak secondary endpoint after a literature paper the 505(b)(2) package leans on getting retracted.

Hypotheses to test

• Authorize To resubmit, meet, now; advisory-committee question list that exposes a weak secondary endpoint already has the discriminator after a literature paper the 505(b)(2) package leans on getting retracted.
• Keep Pause the program in force until advisory-committee question list that exposes a weak secondary endpoint is completed after a literature paper the 505(b)(2) package leans on getting retracted for regulatory-affairs lead.
• Treat advisory-committee question list that exposes a weak secondary endpoint as To resubmit, meet, because both readings appear after a literature paper the 505(b)(2) package leans on getting retracted.
• Refuse a Pharma & Life Sciences close: regulatory-affairs lead does not have the page to resubmit, meet, or turns on in advisory-committee question list that exposes a weak secondary endpoint.

Analysis required

• Check whether advisory-committee question list that exposes a weak secondary endpoint supports the labeled claim regulatory-affairs lead would keep.
• Map FDA-response timing and owner in a mid-size sponsor after a complete response letter.
• Trace CMC, labeling, or pharmacovigilance facts in advisory-committee question list that exposes a weak secondary endpoint after a literature paper the 505(b)(2) package leans on getting retracted.
• For this Pharma & Life Sciences FDA Response and Labeling file, read advisory-committee question list that exposes a weak secondary endpoint against a literature paper the 505(b)(2) package leans on getting retracted and write the one fact that would move to resubmit, meet, or for regulatory-affairs lead.

Recommendation